disease 2,252 words KG: ent-dise-8532989e
Contents

down-syndrome-alzheimers

Disease Info
Prenatal to adolescenceSoluble amyloid-beta levels are elevated; diffuse plaques appear in some individuals as early as age 12–15
20s–30sDiffuse amyloid-beta plaques become widespread, particularly in frontal and temporal cortices
30s–40sNeuritic plaques with dense amyloid cores appear, accompanied by early cerebral-amyloid-angiopathy (CAA)
>40 yearsFull AD neuropathology with extensive plaques, meeting Braak amyloid stages equivalent to moderate-to-severe AD
Prodromal phase (typically 30s–40s)Subtle changes in adaptive behavior, apathy, executive dysfunction, and personality changes that may precede memory impairment
Early dementia (typically 40s–50s)Progressive memory loss, disorientation, decline in activities of daily living, and language deterioration
Late dementiaGlobal cognitive decline, seizures (affecting 50–75% of DS-AD patients), incontinence, dysphagia, and loss of ambulation
DatabasesOMIMOrphanetClinicalTrialsPubMed

No AI portrait yet

Knowledge Graph

Agent Input

💡 Improve this page

🌐 Cross-references

OMIMMeSHWikipedia

Related Hypotheses (19)

APOE-Dependent Autophagy Restoration
Score: 0.88
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.86
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.79
Competitive APOE4 Domain Stabilization Peptides
Score: 0.78
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.78
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.76
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
APOE Isoform Expression Across Glial Subtypes
Score: 0.74
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
Aquaporin-4 Polarization Rescue
Score: 0.73
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
APOE Isoform Conversion Therapy
Score: 0.72
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.72
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.71
Palmitoylation-Targeted BACE1 Trafficking Disruptors
Score: 0.69
Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.68
Heat Shock Protein 70 Disaggregase Amplification
Score: 0.62
Circadian-Gated Maresin Biosynthesis Amplification
Score: 0.56
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54

Related Analyses (11)

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · completed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived

Related Experiments (1)

ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.